Alltracel commences co-funded development on PhytopeuticsTM with a major global leader in the functional cosmetic/cosmeceutical ingredient market - successful conclusion to this six month joint product development program will lead to a formal alliance agreement with this global market leader - 7.00am June 12th, 2007: Dublin, Ireland & Prague, Czech Republic Alltracel Pharmaceuticals Plc., ("Alltracel", or "the Company"), (AIM:AP.L), the Healthcare Innovation Group focused on the Wound Care, Oral Care, Cardiovascular Health and Cosmeceutical markets, is today pleased to announce it has begun a six month co-funded product development programme with a leading global commercialisation partner in the cosmeceuticals ingredient market. The successful conclusion of the programme will lead to both parties entering into an alliance to commercialise the PhytopeuticsTM range of dermal health solutions in the global cosmeceutical market. The scope of the co-funded product development programme will focus on development of the following proven PhytopeuticsTM properties: - Collagen and Elastin Stimulation - replenishing the skins natural strength and elasticity to combat the signs of ageing. - Moisturisation / Skin Hydration - retaining the skins moisture and helping reduce the signs of skin damage and ageing - Anti-Oxidation - boosting the skin's defenses against damage Alltracel's CEO, Tony Richardson, commented: "PhytopeuticsTM provides a full range of dermal health solutions for all ages of skin. This co-funded development programme is for six months and involves three distinct phases. The successful outcome will lead to a formal alliance between Alltracel and our partner who is a global leader in the functional skin care ingredient market with specific expertise in the final formulation of complex skin care products. We are very excited about working closely with this global leader whose experience and reputation in this market further strengthens the PhytopeuticsTM offering and brings Alltracel a step closer to entering the high consumption, high margin international cosmeceutical marketplace." Ends For Further Information Contact: Dublin: Karen Muldowney Alltracel: +353 1 235 2162 press@alltracel.com London: Deborah Scott Financial Dynamics: +44 207 831 3113 Notes to Editors: PhytopeuticsTM (www.phytopeutics.com) is a range of dermal health solutions derived from Alltracel's patented technology and targeting the functional cosmetic/cosmeceuticals market. Alltracel, (AIM: AP.L) (www.alltracel.com) the Healthcare Innovation Group is focused on taking proprietary technology from research right through to commercialisation in the global healthcare market. Alltracel Pharmaceuticals Plc., ("Alltracel") was founded in 1996 and is a public company which listed on London's Alternative Investment Market in July 2001. With corporate headquarters in Dublin, Ireland; Alltracel has a commercial office in London, England; R&D subsidiary in the Czech Republic and manufacturing facilities in Shenzhen, China. Alltracel also has a wide network of research, development and manufacturing partners in Europe, Asia and North America. Alltracel operates via two main divisions Alltracel Healthcare Group and Alltracel Healthcare Technologies: Alltracel Healthcare Group is focused on the commercialisation effort behind proven innovative technologies and services for the global healthcare market. Alltracel Healthcare Group has a range of stake holdings, joint ventures and wholly owned business units operating in a variety of healthcare categories including Wound Care, Oral Care, and Cardiovascular Health. - Alltracel's specialist Oral Care subsidiary Westone (www.westoneproducts.com) is headquartered in London, England and is the leading contract supply and manufacturing partner for the European private label inter-dental market. Westone also partners with a number of leading oral care brands internationally. - Alltracel's specialist Nanotechnology subsidiary Nanopeutics s.r.o. (www.nanopeutics.net) is headquartered in Liberec in the Czech Republic and is dedicated to the commercialisation of NanospiderTM technology for the global healthcare market. Alltracel Healthcare Technologies specialises in innovation, research, development and the deployment of proprietary technology in the global healthcare market. Alltracel Healthcare Technologies has established a substantial intellectual property portfolio with patents in a number of healthcare applications areas such as Wound Care, Cardiovascular Health and Skin Care. m-docTM & PhytopeuticsTM are trademarks of Alltracel Pharmaceuticals plc. NanospiderTM and NanopeuticsTM are trademarks controlled by Nanopeutics s.r.o. This information is provided by RNS The company news service from the London Stock Exchange
Alltracel Pharmaceuticals Plc announces Re Agreement
| Source: Alltracel Pharmaceuticals Plc
DUBLIN, IRELAND--(Marketwire - June 12, 2007) -